Active Ingredient History
Proflavine is an acriflavine derivative used as a topical disinfectant agains gram-positive bacteria. Proflavine is toxic and carcinogenic in mammals and so it is used only as a surface disinfectant or for treating superficial wounds. Proflavine acts by interchelating DNA (intercalation), thereby disrupting DNA synthesis and leading to high levels of mutation in the copied DNA strands. This prevents bacterial reproduction. Proflavine was investigated for photodynamic theraphy of herpes but was discontinued due to several presentations of post-treatment Bowen's disease and higher lesion recrudescence periods. Proflavine is also investigated as a topical contrast agent for imaging and diagnosis of esophageal, oral, colon, cervical, uterine cancer and polyps. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Barrett Esophagus (Phase 2)
Carcinoma, Mucoepidermoid (Early Phase 1)
Carcinoma, Squamous Cell (Phase 1/Phase 2)
Colonic Polyps (Phase 1)
Gastroesophageal Reflux (Early Phase 1)
Herpes Genitalis (Phase 2)
Mouth Diseases (Early Phase 1)
Neoplasm Metastasis (Early Phase 1)
Neoplasms (Phase 2)
Neoplasms, Squamous Cell (Early Phase 1)
Stomach Neoplasms (Phase 1)
Urinary Tract Infections (Phase 4)
Uterine Cervical Neoplasms (Phase 1)
Uterine Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue